Capivasertib, in combination with fulvestrant, is approved in the US for the treatment of HR-positive/HER2-negative locally advanced or metastatic BC with ≥1 PIK3CA, AKT1, and/or PTEN alterations, following disease progression on ≥1 ET-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant endocrine. This evidence concerns the gene AKT1 and breast cancer.